Introduction: Postherpetic neuralgia (PHN), a type of peripheral neuropathic pain (pNeP), is
INTRODUCTION
Peripheral neuropathic pain (pNeP) is a general pain disorder caused by a lesion or disease of the peripheral somatosensory nervous system and occurs frequently with diabetes or following herpes zoster reactivation. The symptoms of pNeP may include numbness, tingling, weakness, and burning, and may lead to more severe events such as higher blood pressure, vomiting, and diarrhea. Postherpetic neuralgia (PHN) is a persistent, debilitating type of pNeP lasting months to years and is the most common complication of herpes zoster. PHN/pNeP severity is a primary predictor of negative health impact, with the more severe patients reporting low levels of health-related quality of life [1] .
China's rapidly aging population portends a coming transition from acute illness as its primary health challenge to chronic diseases [2] , which require long-term, tailored solutions based on individual patient characteristics. It is generally believed that the prevalence of pNeP and PNP will continue to increase globally due to the aging of the population and higher survival rates from conditions that are associated with pNeP (such as cancer, HIV infection, and diabetes) [3] .
Vera-Llonch et al. [4] developed a 12-week stochastic simulation model to examine the treatment of pNeP; this work was adapted by Tarride et al. [5] into a cost-effectiveness model comparing pregabalin versus gabapentin in the management of diabetic peripheral neuropathy (DPN) and PHN in a Canadian setting.
Compared to gabapentin, pregabalin was projected to result in 6 and 9 additional days with no or mild pain, and 0.005 and 0.009 quality-adjusted life years (QALYs), for patients with DPN and PHN, respectively. The adapted Canadian model utilized a global perspective to facilitate future adaptations to the healthcare perspectives of additional countries.
Although the cost-effectiveness of pregabalin has previously been assessed in the UK [6] and Spain [7] , no comparable studies to date have assessed the costs and health impacts for China.
The objective of this study was to assess the cost-effectiveness of pregabalin compared with gabapentin in pNeP and PHN from a Chinese healthcare perspective using a China-localized adaptation of the Tarride et al. [5] model.
METHODS

Approach
We adapted the Tarride et al. [5] decision model to evaluate the short-term incremental cost-effectiveness of pregabalin versus gabapentin in China [8] . The analysis was conducted from a Chinese health system perspective using a 12-week time horizon based on duration of follow-up in the pregabalin clinical trials [9, 10] 
Model Structure
We utilized a three-state (severe, moderate, or no pain) Markov model ( Fig. 1 ) to represent variable pain scores and associated health state utilities and costs, with a cycle length of 1 day.
For any given patient, pain was assumed to vary daily, thus patients could move from one state to another with each cycle. Patient resource use was calculated using a decision analytic model ( Fig. 2 ) based on the probability of a general practitioner visit followed by subsequent probabilities for additional resources.
Model Outcomes
The primary model outcomes were: (1) post-treatment pain score, (2) total number of days with no or mild pain, (3) drug costs, and (4) total medical-care services costs. Secondary outcomes included: (1) mean number of days with 30%, 40% and 50% reduction in pain scores, (2) mean number of days C2 or 3 point reduction in pain, and (3) cost per additional day with no or mild pain. Pain was measured on an 11-point numeric pain rating scale (0 = no pain, 10 = severe pain). Severe pain was classified as pain severity from 7 to 10, moderate pain from 4 to 6, and mild pain from 1 to 3.
Population
We modeled the patient population based on clinical trial data of patients with pNeP which includes patients with both PHN and DPN, and/ or PHN. Patients had moderate to severe pain at treatment initiation, and received an average daily dose of 372 mg/day for pregabalin and 2400 mg/day for gabapentin, although dosage was modifiable through scenario analysis. Patient pain was assumed to be intractable to therapies for underlying conditions. (Table 1 ). Efficacy estimates (Table 2) were obtained from published literature and were modeled for each week as the percentage reduction in baseline pain score [1] : pregabalin efficacy in pNeP was taken from Protocol 1008-155 [9] and has been used previously [4] ; gabapentin efficacy in pNeP was taken from the pooled analysis of two randomized clinical trials [12, 13] .
The probability of a doctor visit was unique to a patient's pain score on any given week and reflected results from the key opinion leader survey (Table 3) . Patients who visited a doctor utilized healthcare resources according to results from the survey (Table 4) . Drug costs included the cost of pregabalin and gabapentin (Table 5 ). The cost of pregabalin was based on the average trial dose of 372 mg per day.
Assumptions
We assumed clinical management was similar for PHN and DPN patients. Adverse events were not included in the model because no clinically relevant differences exist between pregabalin and gabapentin within the 12-week time horizon. Rates of therapy discontinuation due to adverse events or lack of efficacy were also assumed to be the same between therapies. We assumed primary care providers clinically managed all patients, and that the likelihood Fig. 2 Resource utilization decision tree. A probability of a doctor's visit is assigned to patients in each health state, patients then have probabilities of consuming additional resources and costs if they visit a doctor. GP general practitioner The pre-treatment pain score distributions were sourced from the physician survey. The distribution shows the percentage of patients within each pain score threshold for both the pNeP and PHN populations pNeP peripheral neuropathic pain, PHN postherpetic neuralgia that patients will visit their primary care provider in a given week was a function of average level of pain. The efficacy of additional healthcare services is unknown, particularly if used in conjunction with pregabalin or other pharmacotherapy, thus we did not assign health benefits to them.
Analysis
The 12-week model was designed to estimate the impact of pharmacotherapy on daily pain experience using Bayesian simulation techniques to estimate patients' daily pain experience (measured on 0-10 scale) over time. The expected mean reductions (vs. baseline) in average daily pain scores for therapies of interest were applied to each patient's daily pain scores on a weekly basis to generate expected daily pain scores with treatment. We calculated various summary measures of patient outcomes based on expected daily pain scores for each treatment of interest. Summary measures of the outcomes were combined with utilization of healthcare services, costs of care, and health state utilities to calculate the cost-effectiveness of pregabalin versus gabapentin. We explored parameter uncertainty using a probabilistic sensitivity analysis of 1000 simulations of 1000 patients each, and calculated the mean and 95% credible interval for each model outcome. The weekly percentage reductions in pain score are shown for each week of the model for both medications and populations. These percentages contribute to the transition probabilities within the Markov model Severe pain (7.0 to \10.0)
19.11
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RESULTS
The results of the pNeP and PHN analyses are summarized in Table 6 . The mean pre-treatment pain scores were 6.7 for patients with pNeP and 7.2 for patients with PHN. At 12 weeks post-treatment initiation, the mean pain scores for the pNeP population were 3.9 and 4.5 for those treated with pregabalin and gabapentin, respectively. In the PHN population, 12-week mean pain scores were 4.2 and 4.9 for patients treated with pregabalin and gabapentin, respectively. Treatment with pregabalin resulted in an additional decrease of 0.6 and 0.7 when compared to patients receiving gabapentin in the pNeP and PHN populations, respectively.
In the pNeP population, pregabalin resulted in an increase of 9.5 days of no or mild pain, a decrease of -6.1 days of moderate pain, and a decrease of -3.5 days of severe pain compared to gabapentin. Pregabalin had more mean days with a C30% (8.3 days), 40% (9.7 days), and 50% reduction (10.8 days) in pain when compared with gabapentin. In the PHN population, pregabalin resulted in an increase of 9.6 days of no or mild pain, a decrease of Resource utilization probabilities and costs were sourced from the physician survey. The probability of a doctor's visit was based on the patient's health state ( Table 3 ). The probabilities of the other resources being utilized were assigned to patients who visited the doctor The cost per additional day of mild/no pain was calculated for both patient populations (Tables 7, 8 ). The total costs were higher in both populations in patients treated with pregabalin. In pNeP patient pregabalin resulted in an additional $427 in total costs when compared with gabapentin. For the PHN population, total costs were an additional $429 for pregabalin treatment compared to gabapentin. [14] . Therefore, it is imperative to make more treatment options available to patients, so that a multifaceted approach to treatment is possible for each unique expression of patient pain. Given the increasing societal burden of these chronic diseases in China, government payers may need to increase coverage for effective treatments such as pregabalin. This will provide the necessary access to the medications that can improve The results of the peripheral neuropathic pain population analysis are shown. The results are presented as the mean (95% confidence interval) of the simulations [20] [21] [22] . Lastly, we recognize that the QALY may not be the measure of choice for the Chinese health system, and that pain-free days are more likely to have buy-in from patients and clinicians alike. 
CONCLUSIONS
Pregabalin appears to be an effective treatment for PHN and pNeP at an incremental cost per additional day of mild/no pain of $45, leading to improved outcomes including lower pain scores and an increase in days with no or mild pain, in a Chinese setting. Adding pregabalin to the treatment paradigm for pNeP/PHN would provide physicians with an additional weapon to treat patients with pNeP/PHN that provides a great value.
